TY - JOUR T1 - Evolution of patients with Bronchiolitis Obliterans Syndrome (BOS) secondary to allogenic Haematopoietic Stem Cell Transplant (HSCT) JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA633 VL - 54 IS - suppl 63 SP - PA633 AU - Adrian Martinez Vergara AU - María Churruca Arróspide AU - Patricia López Pereira AU - Elena Sola Aparicio AU - Rosa María Girón Moreno AU - Beatriz Aguado Bueno AU - Beatriz Aldave Orzaiz AU - Ana Sánchez Azofra AU - Joan Soriano Ortiz AU - Julio Ancochea Bermúdez Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA633.abstract N2 - Background: Graft versus host disease (GVHD) is a complication of allogenic hematopoietic stem cell transplant (HSCT). Our study aim was to describe the prevalence, clinical characteristics and survival of BOS in patients who underwent HCT in the last 10 years.Methods: We have analyzed the prevalence and clinical variables of 289 cases of HCT that were performed in a tertiary hospital from January 2009 to June 2018.Results: 42 patients with BOS diagnosis were included, 23 men. BOS prevalence was 14.8%. The mean age for transplantation was 48.39 ± 12.74 years. The main diseases for which HCT was performed were acute myeloid leukemia (34.8%) and myelodysplastic syndrome (28.3%). The mean pre-transplant FEV1 was 96.28% ± 11.55 and at the time of BOS diagnosis was 64.6% ± 24.43. At six months after diagnosis was 66.86% ± 31.08. Sputum culture was made in 19 patients, being positive in 10 cases for A. fumigatus, 7 for P. aeruginosa, 2 for H. influenzae and S. Maltophilia. Most common Chest computed tomography findings were ground glass and bronchiectasis in 56.4%. The survival median was 9 months. 11 of the GVHD was exclusively pulmonary, whereas, in the rest of patients (74,4%), pulmonary disease was associated to other organs.Conclusion: BOS is a high mortality complication that appears in a 15% of allogeneic HCT. Its management must be multidisciplinary because It may develops alone or associated with other organs disease. Respiratory function tests are necesary in extrapulmonary GVHD cases, as well as in patients with respiratory symptoms to detect premature pulmonary involvement and to establish early treatment.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA633.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -